ZA201104011B - Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases - Google Patents

Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Info

Publication number
ZA201104011B
ZA201104011B ZA2011/04011A ZA201104011A ZA201104011B ZA 201104011 B ZA201104011 B ZA 201104011B ZA 2011/04011 A ZA2011/04011 A ZA 2011/04011A ZA 201104011 A ZA201104011 A ZA 201104011A ZA 201104011 B ZA201104011 B ZA 201104011B
Authority
ZA
South Africa
Prior art keywords
cilostazol
vascular
treatment
metabolic diseases
nitrate derivatives
Prior art date
Application number
ZA2011/04011A
Other languages
English (en)
Inventor
Dirk Sartor
Armin Scherhag
Original Assignee
Cardiolynx Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiolynx Ag filed Critical Cardiolynx Ag
Publication of ZA201104011B publication Critical patent/ZA201104011B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2011/04011A 2008-12-02 2011-05-31 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases ZA201104011B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170435A EP2194048A1 (en) 2008-12-02 2008-12-02 Nitrate esters for the treatment of vascular and metabolic diseases
PCT/EP2009/066159 WO2010063724A1 (en) 2008-12-02 2009-12-01 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Publications (1)

Publication Number Publication Date
ZA201104011B true ZA201104011B (en) 2012-02-29

Family

ID=40456966

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/04011A ZA201104011B (en) 2008-12-02 2011-05-31 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Country Status (14)

Country Link
US (1) US8426597B2 (enExample)
EP (2) EP2194048A1 (enExample)
JP (1) JP2012510502A (enExample)
KR (1) KR20110088598A (enExample)
CN (1) CN102245583A (enExample)
AU (1) AU2009324123A1 (enExample)
BR (1) BRPI0923300A2 (enExample)
CA (1) CA2745252A1 (enExample)
IL (1) IL213214A0 (enExample)
MX (1) MX2011005744A (enExample)
RU (1) RU2011126607A (enExample)
SG (1) SG171423A1 (enExample)
WO (1) WO2010063724A1 (enExample)
ZA (1) ZA201104011B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080925A1 (es) 2010-04-19 2012-05-16 Cardiolynx Ag Derivados de valsartan que portan donadores de no para el tratamiento de las enfermedades vasculares y metabolicas
TW201204355A (en) 2010-06-02 2012-02-01 Cardiolynx Ag Nitrate derivatives of pioglitazone
PL2888373T3 (pl) 2012-08-21 2018-08-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
ES2701062T3 (es) 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
ES3057437T3 (en) 2012-08-21 2026-03-02 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス,インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CA2882560C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ.ベー. リスペリドンに対する抗体及びその使用
CN114044766B (zh) * 2021-10-09 2022-12-27 张北北九食品检验技术有限公司 放射性同位素碳-14标记的呋虫胺和中间体及其制备方法和应用
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US6148496A (en) 1999-04-09 2000-11-21 The Procter & Gamble Company Method for making a seamless apertured metal belt
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
DK1653950T3 (da) 2003-07-31 2008-05-26 Nicox Sa Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
EP1922069A2 (en) * 2005-08-08 2008-05-21 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Also Published As

Publication number Publication date
JP2012510502A (ja) 2012-05-10
KR20110088598A (ko) 2011-08-03
AU2009324123A1 (en) 2011-07-21
BRPI0923300A2 (pt) 2019-07-16
CN102245583A (zh) 2011-11-16
MX2011005744A (es) 2011-06-20
US20110230520A1 (en) 2011-09-22
EP2194048A1 (en) 2010-06-09
SG171423A1 (en) 2011-07-28
IL213214A0 (en) 2011-07-31
US8426597B2 (en) 2013-04-23
EP2367803A1 (en) 2011-09-28
CA2745252A1 (en) 2010-06-10
WO2010063724A1 (en) 2010-06-10
RU2011126607A (ru) 2013-01-10

Similar Documents

Publication Publication Date Title
IL213214A0 (en) Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
IL209282A (en) History of n-pipridine-3-yl-2-benzimidazole carboxamide and drugs containing it for the treatment of cardiovascular disease
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
EP2318005A4 (en) NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
SI2328417T1 (sl) Spojine, sestavki in postopki za zdravljenje beta amiloidnih bolezni in sinukleinopatije
IL218143A0 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
PL2234631T3 (pl) Związki i metody stosowane w terapii choroby naczyniowej
GB0909297D0 (en) Composition for the treatment of skin conditions
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea